RxDoctor Payments Data

Nicoleta Daraban, MD

Internal Medicine · Saratoga Springs, NYNPI 1538353008

Payments from drug & device makers

$1,232in general payments, 2019–2025

Across 50 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$268
  • Novartis$222
  • Regeneron Healthcare Solutions, Inc.$139
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$132
  • E.r. Squibb & Sons, L.L.C.$103
  • Johnson & Johnson$65
  • plus $304 from 10 others

What the payments were for

  • Food & beverage$1,13292%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,232 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$101,558
Medicare patients
1,426
Services billed
2,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban785$979,623
XareltoRivaroxaban280$313,908
EntrestoSacubitril/Valsartan136$179,705
FarxigaDapagliflozin Propanediol111$149,986
BrilintaTicagrelor79$83,608
Repatha SureclickEvolocumab79$73,824
JardianceEmpagliflozin61$70,952
MultaqDronedarone Hcl37$45,289
Praluent PenAlirocumab51$37,808
WegovySemaglutide23$34,314
Repatha SyringeEvolocumab20$17,585
Metoprolol Succinate1,069$15,696
Atorvastatin Calcium1,048$13,199
Rosuvastatin Calcium698$12,514
Verapamil Er PmVerapamil Hcl24$10,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$979,623785 claims
Johnson & JohnsonXarelto$65$313,908280 claims
AstraZenecaFarxiga, Brilinta$268$233,595190 claims
NovartisEntresto$222$179,705136 claims
Boehringer IngelheimJardiance$53$70,95261 claims
Esperion Therapeutics, Inc.Nexletol$26$9,38916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Saratoga Springs

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →